- Home
- ACIU vs MBI Comparison
ACIU vs MBI Comparison
Compare ACIU & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- MBI
- Stock Information
- Founded
- ACIU 2003
- MBI 1973
- Country
- ACIU Switzerland
- MBI United States
- Employees
- ACIU N/A
- MBI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- MBI Property-Casualty Insurers
- Sector
- ACIU Health Care
- MBI Finance
- Exchange
- ACIU Nasdaq
- MBI Nasdaq
- Market Cap
- ACIU 247.4M
- MBI 278.8M
- IPO Year
- ACIU 2016
- MBI 1987
- Fundamental
- Price
- ACIU $1.98
- MBI $5.01
- Analyst Decision
- ACIU Strong Buy
- MBI Buy
- Analyst Count
- ACIU 2
- MBI 2
- Target Price
- ACIU $12.00
- MBI $6.75
- AVG Volume (30 Days)
- ACIU 197.4K
- MBI 349.9K
- Earning Date
- ACIU 03-13-2025
- MBI 05-08-2025
- Dividend Yield
- ACIU N/A
- MBI N/A
- EPS Growth
- ACIU N/A
- MBI N/A
- EPS
- ACIU N/A
- MBI N/A
- Revenue
- ACIU $30,136,397.00
- MBI $27,000,000.00
- Revenue This Year
- ACIU $120.91
- MBI N/A
- Revenue Next Year
- ACIU $13.82
- MBI N/A
- P/E Ratio
- ACIU N/A
- MBI N/A
- Revenue Growth
- ACIU 84.51
- MBI 285.71
- 52 Week Low
- ACIU $1.95
- MBI $3.22
- 52 Week High
- ACIU $4.98
- MBI $7.46
- Technical
- Relative Strength Index (RSI)
- ACIU 27.05
- MBI 34.01
- Support Level
- ACIU $1.95
- MBI $5.01
- Resistance Level
- ACIU $2.05
- MBI $5.58
- Average True Range (ATR)
- ACIU 0.13
- MBI 0.26
- MACD
- ACIU -0.02
- MBI 0.01
- Stochastic Oscillator
- ACIU 6.38
- MBI 10.53
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About MBI MBIA Inc.
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.